Published Papers
Cure Alzheimer’s Fund is proud to present a total of 34 published papers that result from Cure Alzheimer’s Fund support.
Most of the papers grow out of the Alzheimer’s Genome Project (AGP) as that is where most of our investment has gone. The AGP has met its goal of identifying most of the remaining genes that affect risk or provide protection from Alzheimer’s disease in three years for about $3 million. 70 genes have been newly identified and are now available for follow-up by Cure Alzheimer’s Fund supported researchers and others.
The other papers represent innovative and in most cases collaborative investigations of more “translational” research --- research enabled by the discovery of the first four genes which have been known to the field for some time. These papers point to ways for potentially faster development of therapies that affect the disease mechanism, not just the symptoms.
We thank all the researchers and lab personnel for their dedication and commitment to the common mission of ending this disease, and we congratulate all of them for the important work reflected in these papers. We are also grateful to all of those who literally made this work possible. Without those of you who have supported Cure Alzheimer’s Fund projects through your generosity, these papers and the momentum forward they represent would not exist.
2010
Gianni D, Li A, Tesco G, McKay KM, Moore J, Raygor K, Rota M, Gwathmey JK, Dec GW, Aretz T, Leri A, Semigran MJ, Anversa P, Macgillivray TE, Tanzi RE, delMonte F. Protein Aggregates and Novel Presenilin Gene Variants in Idiopathic Dilated Cardiomyopathy. Circulation: Journal of the American Heart Association.
Zhang C, Browne A, Child D, DiVito JR, Stevenson JA, Tanzi RE, Loss-of-Function of ATXN1 Increases Amyloid-Beta Levels by Potentiating Beta-Secretase Processing of APP. Journal of Biological Chemistry.
2009
Bertram L, Alzheimer's Disease Genetics: Current Status and Future Perspectives. International Review of Neurobiology, Vol. 84, 2009.
Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H . Caffeine suppresses β-amyloid levels in plasma and brain of Alzheimer’s transgenic mice. Journal of Alzheimer's disease, 2009.
Hoos MD, Ahmed M, Smith SO, Van Nostrand WE, Myelin basic protein binds to and inhibits the fibrillar assembly of AB42 in vitro. Biochemistry 48: 4720-4727, 2009.
Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C, Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284, 4230-4237.
Schjeide BM, Hooli B, Parkinson M, Hogan M, DiVito J, Mullin K, Blacker D, Tanzi RE, Bertram L. . GAB2 as an Alzheimer Disease Susceptibility Gene. . Arch Neurol/Vol 66(No. 2), Feb 2009.
Schjeide BM, Hooli B, Parkinson M, Hogan MF, DiVito J, Mullin K, Blacker D, Tanzi RE, Bertram L. GAB2 as an Alzheimer Disease Susceptibility Gene: Follow-up of Genomewide Association Results. Arch Neurol, Feb 2009; 66: 250 - 254.
Huttunen HJ, Peach C, Bhattacharyya R, Barren C, Pettingell W, Hutter-Paier B, Windisch M, Berezovska O, Kovacs DM. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. The FASEB Journal, July 2009.
Kaufer D, Gandy S. APOE4 and Bapineuzumab: Kindling Pharmacogenomics in Alzheimer's Disease Therapeutics. Neurology.
Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-Beta Dynamics are Regulated by Orexin and Sleep-Wake Cycle. Science Express.
Kim M, Suh J, Romano D, Truong MH, Mullin K, Hooli B, Norton D, Tesco G, Elliot K, Wagner SL, Moir RD, Becker KD, Tanzi RE. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate alpha-secretase activity. Human Molecular Genetics, 2009 Vol 18.
Won S, Bertram L, Becker D, Tanzi RE, Lange C. Maximizing the Power of Genome-Wide Association Studies: A Novel Class of Powerful Family-Based Association Tests. Journal of International Chinese Statistical Association.
Steele JW, Kim HS, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P. Hyslop PSG, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Molecular Neurodegeneration.
Lublin AL, and Gandy S. Amyloid-B Oligomers: Possible Role as Key Neurotoxins in Alzheimer's Disease. Mount Sinai Journal of Medicine 77:1-7, 2010.
2008
Berman DE, Dall’Armi C, Voronov SV, McIntire LBJ, Zhang H, Moore AZ, Staniszewski A, Arancio O, Kim T, Di Paolo G. . Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4, 5-bisphosphate metabolism. . Nature Neuroscience, 2008.
Bertram L, Lange CL, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BMM, Hooli B, DeVito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE. Genome-wide association analysis reveals novel Alzheimer’s disease susceptibility loci in addition to APOE. . Am. J. Hum. Genet. Oct. 2008: 83:623-632.
Bertram L, Schjeide BM, Hooli B, Mullin K, Hiltunen M, Soininen H, Ingelsson M, Lannfelt L, Blacker D, Tanzi RE. . No association between CALHM1 and Alzheimer's disease risk. . Cell. 2008 Dec 12;135(6):993-4.
Bertram L, Tanzi RE. Thirty Years of Alzheimer’s Disease Genetics: Systematic Meta-analyses Herald a New Era. Nature Reviews Neurosci, 2008.
Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science, 2008.
Cotton RG, Auerbach AD, Axton M, Barash CI, Berkovic SF, Brookes AJ, Burn J, Cutting G, den Dunnen JT, Flicek P, Freimer N, Greenblatt MS, Howard HJ, Katz M, Macrae FA, Maglott D, Moslein G, Povey S, Ramesar RS, Richards CS, Seminara D, Smith TD, Sobrido MJ, Solbakk JH, Tanzi RE, Tavtigian SV, Taylor GR, Utsunomiya J, Watson M, The Human Variome Project. Science. 2008 Nov 7:322(5903):861-2.
Glabe, C. G. Structural classification of toxic amyloid oligomers. J Biol Chem 283, 29639-29643.
Huttuner HJ, utter-Paier B, Barren C, Peach C, Havas D, Duller S, Xia W, Frosch MP, Windisch M, Kovacs DM. . The ACAT Inhibitor CI-I0II Reverses Diffuse Brian Amyloid Pathology in Aged hAPP Mice. . Proceedings of the National Academy of Science, 2008.
Kavvoura FK, McQueen MP, Khoury MJ, Tanzi RE, Bertram L, Ioannidis JPA. . Evaluation of the potential excess of statistically significant findings reported genetic association studies: application to Alzheimer's disease. Am. J. Epidemiol. 2008.
Schaffer B, Bertram L, Miller L, Mullin K, Weintraub S, Johnson N, Bigio E, Mesulam M, Wiedau-Pazos M, Jackson G, Cummings J, Cantor R, Levey A, Tanzi RE, and Geschwind D. . Association of GSK3B with Alzheimer's Disease and Frontotemporal Dementia. . Archives Neurol., Oct. 2008; 65:1368-1374.
Xie Z, Culley DJ, Dong Y, Zhang G, Zhang B, Moir RD, Frosch MP, Crosby G, Tanzi RE. . The common inhalation anesthetic isoflurane induces caspase activation and increases Ab level in vivo. . Annals of Neurology, De. 2008; Volume 64, Issue 6.
Zhang B, Dong Y, Zhang G, Moir RD, Xia W, Yue Y, Tian M, Culley DJ, Crosby G, Tanzi RE, Xie Z. The inhalation anesthetic desflurane induces caspase activation and increases amyloid-beta protein levels under hypoxic conditions. . J Biol Chem., 2008; 2;283(18):11866-75.
Zhang G, Dong Y, Zhang B, Ichinose F, Wu X, Culley DJ, Crosby G, Tanzi RE, Xie Z. Isoflurane-induced caspase-3 activation is dependent on cytosolic calcium and can be attenuated by memantine. . J Neurosci, 2008; 28:4551-60.
Cirrito JR, Kang J, Lee J, Stewart FR, Verges D, Silverio LM, Bu G, Mennerick S, Holtzman DM. . Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. . Neuron, 2008.
Schjeide BM, McQueen MB, Mullin K, DiVito J, Hogan MF, Parkinson M, Hooli B, Lange C, Blacker D, Tanzi RE, and Bertram L. Assessment of Alzheimer's disease case-control associations using family-based methods. Neurogenetics DOI 10.1007/s10048-008-1051-3.
2007
Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE. Decreased catalytic activity of the insulin degrading enzyme in chromosome 10-linked Alzheimer’s disease families. . Biol Chem, 2007; 282(11):7825-32.
McQueen MB, Bertram L, Lange C, Becker KD, Albert MS, Tanzi RE, Blacker D. . Exploring Candidate Gene Associations with Neuropsychological Performance. . Am J Med Genet B Neuropsychiatr Genet, 2007; 144(8):987-91.
Tesco G, Koh YH, Kang E, Cameron A, Das S, Sena-Esteves M, Hiltunen, Yang S-H, Zhong Z, Shen Y, Simpkins J, Tanzi RE. . Depletion of GGA3 stabilizes BACE and enhances ateb-secretase activity. Neuron, 2007; 54(5):721-37.
Xie Z, Dong Y, Maeda U, Moir R, Xia W, Culley DJ, Crosby G, Tanzi RE. The Inhalation Anaesthetic Isoflurane Induces a Vicious Cycle of Apoptosis and Aβ Accumulation. J. Neurosci., 2007; 27:1247-1254.
Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C.W., Necula, M., Margot, L., Wu, J., Breydo, L., Thompson, J.L., iet al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2, 1-11.
